Viral Warts (Verrucae)

1. Clinical Overview

Summary

Viral warts are benign epithelial proliferations caused by infection of keratinocytes with Human Papillomavirus (HPV). They represent one of the most common dermatological conditions, affecting up to 10-20% of school-aged children and 3-5% of adults. [1,2]

While predominantly a nuisance condition, warts can cause significant pain (particularly plantar variants), cosmetic distress, and psychosocial impact. In immunocompromised individuals, warts may become extensive, recalcitrant to treatment, and carry a risk of malignant transformation to squamous cell carcinoma (SCC). [3,4]

The natural history is one of spontaneous resolution in immunocompetent hosts, with 50-70% clearing within 2 years without intervention. However, treatment is often sought for symptomatic relief, cosmetic concerns, or to prevent spread. Current therapeutic approaches include keratolytic agents (salicylic acid), cryotherapy, and immunomodulatory treatments, though recurrence rates remain high across all modalities. [5,6]

Clinical Pearls

The "Black Dot" Sign: Pathognomonic for viral warts. If you pare down the hard skin of a plantar lesion with a scalpel, you will see tiny black dots. These are thrombosed capillaries feeding the wart papillae.

• Corns (Clavi): Have a translucent glassy core without black dots and are located at pressure points.
• Callus: Diffuse thickening of skin without cores or dots, typically over weight-bearing areas.

The Transplant Patient: Patients on long-term immunosuppression (solid organ transplant recipients) have a 50-fold increased risk of cutaneous warts and 100-fold increased risk of SCC arising in warts. Any changing, ulcerated, or rapidly growing wart in a transplant patient must be biopsied urgently to exclude malignant transformation. [7]

Mosaic Warts: A cluster of many small warts that coalesce into a large plaque on the sole of the foot. These are notoriously difficult to treat due to deep extension into dermis and require prolonged therapy.

Koebner Phenomenon: Warts can spread along lines of trauma (shaving, scratching). Linear arrangements of plane warts on the face or legs are classic examination findings.

Dermatoglyphics: Warts distort normal skin lines (fingerprints). This is a key diagnostic feature. When a wart resolves, the normal skin lines return.

---

2. Epidemiology

Demographics

Transmission and Risk Factors

Transmission Routes: [11]

• Direct contact: Skin-to-skin contact with infected individuals
• Indirect contact: Fomites (swimming pool floors, communal showers, gym equipment)
• Autoinoculation: Spread from one body site to another (biting nails, shaving)

Risk Factors: [12,13]

• Immunosuppression (HIV, transplant recipients, immunosuppressive medications)
• Atopic dermatitis (disrupted skin barrier)
• Occupational exposure (butchers, meat handlers, fish workers)
• Communal bathing facilities usage
• Genetic susceptibility (epidermodysplasia verruciformis)
• Previous wart infection (10-year recurrence rate 30%)

Incubation Period: 1-6 months (range: weeks to years) [14]

Etiology (HPV Genotypes)

Human Papillomavirus is a non-enveloped double-stranded DNA virus of the Papillomaviridae family. Over 200 HPV types have been identified, with specific tropism for different anatomical sites. [15]

---

3. Pathophysiology

Viral Entry and Infection

Step 1: Inoculation [16]

• HPV enters basal keratinocytes through microtrauma or micro-abrasions in the stratum corneum
• The virus requires access to the basal layer where actively dividing cells reside
• Plantar warts are more common due to repetitive microtrauma from walking

Step 2: Viral Lifecycle [17]

1. Early Phase: HPV DNA remains episomal (not integrated into host genome)
2. E6 and E7 Oncoproteins: Bind and inactivate p53 and Rb tumor suppressors, driving cell proliferation
3. Viral Replication: As infected cells differentiate and move upward through epidermis, viral DNA replicates
4. Late Phase: L1 and L2 capsid proteins expressed in upper epidermis, viral assembly occurs
5. Viral Shedding: Complete virions shed from surface keratinocytes

Step 3: Immune Evasion [18]

• HPV lifecycle is entirely intraepithelial with no viremic phase
• Minimal inflammation reduces antigen presentation to immune system
• Downregulation of MHC class I expression on infected keratinocytes
• No cytolysis or cell death during viral replication (silent infection)
• This explains both prolonged incubation periods and delayed spontaneous clearance

Histopathological Changes

Microscopic Features: [19]

• Hyperkeratosis: Thickened stratum corneum
• Papillomatosis: Irregular upward projections of epidermis
• Acanthosis: Thickened stratum spinosum
• Koilocytes: Pathognomonic HPV-infected cells with perinuclear halos and irregular, hyperchromatic nuclei
• Dilated capillaries: In dermal papillae (visible as black dots clinically)
• Hypergranulosis: Prominent granular layer with keratohyalin granules

Spontaneous Resolution

Immune-Mediated Clearance: [20]

• Cell-mediated immunity (Th1 response) is crucial for wart clearance
• CD4+ and CD8+ T-cell infiltration marks onset of regression
• Production of IFN-γ, IL-2, and TNF-α
• Development of HPV-specific immunological memory

Timeline: [6]

• 23% clear at 2 months
• 50% clear at 12 months
• 67% clear at 24 months
• Slower clearance in adults and immunocompromised

---

4. Clinical Presentation

Morphological Variants

1. Common Warts (Verruca Vulgaris)

Appearance:

• Firm, hyperkeratotic papules or nodules (2-10mm)
• "Cauliflower" or papillomatous surface
• Rough texture with visible black dots (thrombosed capillaries)
• Skin-colored to grey-brown

Distribution: Hands (especially periungual), fingers, knees, elbows

Features:

• Disrupt normal dermatoglyphics (fingerprint lines)
• May be solitary or multiple
• Painless unless traumatized

2. Plantar Warts (Verrucae Plantaris)

Appearance:

• Flat or slightly raised (pushed into skin by weight-bearing)
• Hyperkeratotic plaque with surrounding callus
• Black dots visible after paring down hyperkeratotic surface
• Distinguished from corns by lack of discrete translucent core

Distribution: Weight-bearing areas of soles (heel, metatarsal heads)

Features:

• Painful on lateral compression (vs corns painful on direct pressure)
• Interrupt dermatoglyphics
• Can grow large (up to 2cm)

Mosaic Warts: Confluence of multiple plantar warts forming large plaque

3. Plane/Flat Warts (Verruca Plana)

Appearance:

• Small (1-5mm), smooth, flat-topped papules
• Skin-colored to light brown
• Minimal hyperkeratosis

Distribution: Face (especially children), dorsal hands, shins

Features:

• Multiple lesions (often 20-100+)
• Linear arrangement due to Koebner phenomenon (autoinoculation from shaving/scratching)
• Often overlooked due to subtle appearance

4. Filiform Warts

Appearance:

• Elongated, finger-like or thread-like projections
• Pedunculated with narrow stalk
• 1-3mm in diameter, up to 10mm in length

Distribution: Face (especially eyelids, lips, nose), neck, beard area

5. Periungual and Subungual Warts

Appearance:

• Around or under nail plate
• Cauliflower-like clusters
• Can distort nail growth

Complications:

• Painful, difficult to treat
• Risk of secondary paronychia
• Nail dystrophy

6. Butcher's Warts

Appearance:

• Large, cauliflower-like lesions
• Typically on hands of meat/fish handlers

Etiology: HPV-7 infection through occupational exposure

Age-Related Presentations

Children:

• Higher prevalence, spontaneous clearance more likely
• Common and plantar warts predominate
• Often multiple lesions

Adults:

• Lower prevalence but more persistent
• Higher recurrence rates
• More likely to seek treatment

Immunocompromised:

• Extensive, confluent lesions
• Atypical morphology
• Resistant to treatment
• Risk of malignant transformation (especially HPV-5, 8 in epidermodysplasia verruciformis)

---

5. Differential Diagnosis

Primary Differentials

Special Diagnostic Considerations

In Immunosuppressed Patients: Always consider malignancy (SCC, verrucous carcinoma) [7]

In Children with Periungual/Anogenital Warts: Consider safeguarding concerns

In Elderly with New "Warts": Low threshold for biopsy to exclude SCC or other malignancy

---

6. Investigations

Clinical Diagnosis

History:

• Duration and progression
• Symptomatology (pain, bleeding, spreading)
• Previous treatments and response
• Immune status (HIV, transplant, immunosuppressive medications)
• Occupational exposures
• Contact with others with warts

Examination:

• Morphology and distribution
• Paring down hyperkeratotic surface to reveal black dots
• Assessment of dermatoglyphic disruption
• Lateral compression test for plantar warts (painful)

Dermoscopy

Typical Features: [21]

• Red or black dots/globules: Thrombosed capillaries in dermal papillae
• Hemorrhagic spots: Due to bleeding from friable capillaries
• Frog spawn/cobblestone appearance: Papillomatous surface
• Loss of dermatoglyphics: Disruption of normal skin lines

Utility: High sensitivity and specificity for differentiating warts from corns/calluses

Histopathology

Indications for Biopsy:

• Diagnostic uncertainty
• Atypical appearance
• Rapid growth or ulceration
• Immunosuppressed patient with changing lesion
• Elderly patient with new "wart"
• Failed multiple treatments

Histological Features:

• Hyperkeratosis and parakeratosis
• Papillomatosis
• Koilocytes in upper epidermis
• Dilated capillaries in dermal papillae
• Hypergranulosis

HPV Typing

Rarely Indicated in Clinical Practice

Potential Uses:

• Research settings
• Recalcitrant cases
• Distinguishing low-risk from high-risk genotypes in genital warts
• Epidemiological studies

Methods: PCR-based detection, in-situ hybridization

Additional Investigations

For Extensive/Recalcitrant Warts:

• HIV test: To exclude immunodeficiency
• Full blood count and lymphocyte subsets: Assess immune function
• Immunoglobulin levels: Exclude hypogammaglobulinemia
• Skin biopsy: Exclude epidermodysplasia verruciformis (genetic testing available)

---

7. Management

Management Algorithm

        CLINICAL DIAGNOSIS OF VIRAL WARTS
                    ↓
       IS TREATMENT NECESSARY?
    (Painful? Cosmetically distressing? 
     Spreading? Occupational impact?)
          ┌──────┴──────┐
         NO            YES
          ↓              ↓
      WATCHFUL      IMMUNOCOMPETENT?
      WAITING           ↓
    (Reassurance)   ┌───┴───┐
    50% resolve    YES     NO
    in 12 months    ↓       ↓
                 FIRST   SPECIALIST
                 LINE    REFERRAL
                  ↓      (Dermatology/
            Salicylic    Infectious
            Acid         Diseases)
            (Daily for
            12 weeks)
                  ↓
            SECOND LINE
           Cryotherapy
           (Liquid N₂)
           Every 2-3 weeks
           for 4-6 cycles
                  ↓
            THIRD LINE
           (Dermatology)
           • Immunotherapy
             (Imiquimod, DPCP)
           • Photodynamic therapy
           • Laser (Pulsed-dye)
           • Curettage ± cautery
           • Intralesional bleomycin
           • Cimetidine (children)

Conservative Management (Watchful Waiting)

Indications: [5,6]

• Asymptomatic lesions
• Young children (high spontaneous clearance)
• Patient preference
• Contraindication to active treatment

Natural History:

• 23% resolve at 2 months
• 50% resolve at 12 months
• 67% resolve at 24 months (immunocompetent individuals)

Patient Education:

• Avoid picking/scratching (autoinoculation risk)
• Cover in communal areas to reduce transmission
• Return if rapid growth, bleeding, or spreading

First-Line: Topical Keratolytic Therapy

Salicylic Acid (15-50%)

Mechanism: Keratolytic agent causes desquamation of infected epidermis

Evidence: Cochrane meta-analysis showed cure rate of 75% vs 48% placebo [5]

Preparations:

• Solutions/paints: Salactol (16.7% SA + 10% lactic acid), Duofilm (16.7% SA)
• Gels: Bazuka (26% SA)
• Plasters: Salatac (50% SA)

Application Protocol:

1. Soak wart in warm water for 5-10 minutes
2. File/pare down dead skin with pumice stone or emery board
3. Apply SA paint/gel to wart only (avoid surrounding skin)
4. Cover with occlusive dressing
5. Repeat daily for 12 weeks minimum

Efficacy:

• Common warts: 70-80% clearance at 12 weeks
• Plantar warts: 60-70% clearance (comparable or superior to cryotherapy)

Adverse Effects:

• Local irritation, pain, erythema
• Chemical burn if applied to normal skin
• Maceration

Contraindications:

• Facial warts (scarring risk)
• Diabetic neuropathy (ulcer risk)
• Peripheral vascular disease
• Pregnancy (theoretical teratogenicity at high doses)

Second-Line: Cryotherapy

Mechanism: Freeze-thaw injury causes keratinocyte necrosis and immunostimulation

Evidence: RCTs show 50-70% clearance after 4 treatments, but NOT superior to salicylic acid for plantar warts [5]

Protocol:

• Liquid nitrogen application via spray or cotton bud
• Freeze time: 10-30 seconds (until 1-2mm white halo)
• Freeze-thaw cycles: Single freeze vs double freeze-thaw (more effective but more painful)
• Interval: Every 2-3 weeks
• Duration: Maximum 4-6 treatments

Efficacy by Site:

• Hand warts: 60-80% clearance
• Plantar warts: 40-60% clearance (thick skin limits efficacy)
• Periungual warts: 50-60%

Adverse Effects:

• Pain during and after treatment (may be severe)
• Blistering (hemorrhagic bullae possible)
• Post-inflammatory hyperpigmentation/hypopigmentation (especially darker skin types)
• Nail damage if periungual
• Scarring (rare)
• Nerve damage if aggressive (plantar warts)

Contraindications:

• Very young children (poor tolerance of pain)
• Peripheral vascular disease
• Raynaud's phenomenon
• Cold urticaria
• Cryoglobulinemia

Comparison to Salicylic Acid: [5]

• No significant difference in efficacy for hand warts
• Salicylic acid SUPERIOR for plantar warts
• Cryotherapy more painful and expensive
• Cryotherapy requires clinic visits
• 2022 Meta-analysis: Cryotherapy showed lower cure rates than other treatments (OR 0.31, 95% CI 0.12-0.78) with substantial heterogeneity for plantar warts [31]

Third-Line and Specialist Treatments

1. Topical Immunotherapy

Imiquimod 5% Cream:

• Toll-like receptor 7 agonist, stimulates innate immunity
• Application: Apply 3-5 times weekly under occlusion
• Efficacy: 50-70% clearance for plane and recalcitrant warts
• Use: Off-label for cutaneous warts (licensed for genital warts)
• Evidence: Multiple small RCTs showing benefit [22]

Contact Immunotherapy (DPCP, SADBE):

• Induces allergic contact dermatitis, stimulating immune response
• Sensitization: Single application of high concentration
• Treatment: Weekly applications of increasing concentrations
• Efficacy: 60-80% in recalcitrant cases
• Availability: Specialist centers only
• Evidence: Effective for periungual warts in head-to-head trials [25]

2. Intralesional Therapies

Intralesional Bleomycin:

• Cytotoxic antibiotic, causes vascular thrombosis
• Injection: 0.1-1 IU per wart
• Efficacy: 60-90% clearance after 1-3 treatments
• Network meta-analysis: Bleomycin superior to Candida antigen (p=0.001) and 5-FU (p=0.009) [26]
• Limitations: Painful, risk of Raynaud's phenomenon, nail dystrophy
• Contraindications: Pregnancy, peripheral vascular disease

Intralesional Candida Antigen:

• Immunotherapy via delayed-type hypersensitivity
• Dose: 0.1-0.3ml of 1:1000 dilution intralesional every 2-3 weeks
• Efficacy: 25-84% complete clearance across studies [27]
• Systematic review (2024): Candida superior to placebo (RR 5.39, 95% CI 3.49-8.33) but not different from MMR, PPD, or vitamin D3 [27]
• Distant warts: 60-80% clearance rate at non-injected sites
• Advantage: Single injection site clears distant warts (systemic immune response)

Purified Protein Derivative (PPD):

• Tuberculin antigen, non-specific immunostimulation
• Dose: 0.1-0.3ml (based on tuberculin skin test reaction size)
• Efficacy: 48-87% complete clearance [28]
• Network meta-analysis: PPD among top-ranked intralesional therapies (OR 39.56 vs placebo) [29]
• Protocol: Intradermal PPD test first, then dose titration

Measles-Mumps-Rubella (MMR) Vaccine:

• Dose: 0.1-0.5ml intralesional every 2-4 weeks for up to 5-8 sessions
• Efficacy: 27-90% complete clearance across 24 RCTs (n=807 patients) [28]
• Network meta-analysis: MMR ranked second after PPD for complete response (OR 17.46 vs placebo) [29]
• Advantage: Widely available, safe profile

Vitamin D3 (Cholecalciferol):

• Antiviral and immunomodulatory effects
• Dose: 0.2ml of 7.5-15mg/ml suspension every 2-3 weeks for 3-4 sessions
• Efficacy: 40-96% complete clearance [28]
• Highest reported response: 96% with 0.2ml of 15mg/ml every 2 weeks [30]
• Mechanism: Activation of toll-like receptors, promotion of keratinocyte apoptosis

3. Procedural Treatments

Curettage and Cautery/Electrosurgery:

• Procedure: Scrape out wart base, cauterize bleeding points
• Efficacy: 60-70% clearance
• Indications: Small, solitary, recalcitrant warts
• Disadvantages: Painful, requires anesthesia, scarring (avoid on soles), recurrence 20-30%

Pulsed-Dye Laser (PDL):

• Mechanism: Selective photothermolysis of wart blood vessels
• Wavelength: 585-595nm
• Efficacy: 50-80% clearance after 2-4 sessions
• Advantages: Minimal pain, no open wound, low scarring risk
• Evidence: Multiple small studies, no large RCTs

CO₂ Laser Ablation:

• Mechanism: Vaporization of wart tissue
• Efficacy: 60-80% clearance
• Disadvantages: Painful, healing time, scarring, HPV-containing plume (infection risk to operator)

4. Photodynamic Therapy (PDT)

• Mechanism: Photosensitizer (5-aminolevulinic acid) + light → reactive oxygen species
• Protocol: Apply ALA, incubate 3-4 hours, irradiate with red light
• Efficacy: 50-70% clearance
• Advantages: Minimal scarring, good cosmetic outcome
• Limitations: Expensive, limited availability, painful during treatment

5. Systemic Therapies

Oral Cimetidine (children):

• Mechanism: Immune modulation (uncertain)
• Dose: 30-40 mg/kg/day divided doses
• Evidence: Mixed/conflicting; may be placebo effect
• Use: Anecdotal reports in extensive pediatric warts

Oral Retinoids (acitretin):

• Indication: Extensive warts in epidermodysplasia verruciformis or immunosuppressed
• Dose: 0.5-1 mg/kg/day
• Monitoring: Liver function, lipids, teratogenicity precautions

Oral Zinc Sulfate:

• Evidence: Some small RCTs showing benefit [32]
• Dose: 10 mg/kg/day (max 600mg)
• Network meta-analysis: No significant difference vs Candida or vitamin D3 [27]
• Tolerability: GI upset common

Treatment by Wart Type

Special Populations

Immunosuppressed Patients

Approach:

• Lower threshold for biopsy (exclude malignancy)
• Consider reducing immunosuppression (if possible, after transplant team discussion)
• Topical imiquimod or intralesional immunotherapy preferred
• Avoid destructive methods (poor healing, high recurrence)
• Regular monitoring for malignant change

Organ Transplant Recipients:

• Warts present in 50-90% by 5 years post-transplant [7]
• Conversion from azathioprine to sirolimus may help clearance
• Topical cidofovir (off-label, limited evidence)

Pregnancy

Safe Options:

• Cryotherapy (preferred)
• Duct tape occlusion
• Gentle physical removal

Avoid:

• Salicylic acid (theoretical teratogenicity at high doses)
• Imiquimod (no safety data)
• Bleomycin (teratogenic)
• Systemic therapies

Counseling: Many warts resolve postpartum as immune function normalizes

Children

Approach:

• Emphasize watchful waiting (high spontaneous clearance)
• Salicylic acid first-line if treatment needed
• Avoid painful procedures (cryotherapy) unless absolutely necessary
• Duct tape occlusion (parent-administered, painless)
• Oral cimetidine (uncertain efficacy but safe)

Safeguarding: Anogenital warts in prepubertal children warrant safeguarding assessment (may indicate vertical transmission, but abuse must be excluded)

---

8. Complications and Sequelae

Direct Complications

Treatment-Related Complications

Malignant Transformation

Verrucous Carcinoma:

• Low-grade variant of squamous cell carcinoma
• Can arise in longstanding warts
• Exophytic, cauliflower-like mass
• Treatment: Wide surgical excision

Risk Factors for Malignancy:

• Immunosuppression (transplant recipients)
• Epidermodysplasia verruciformis (HPV-5, 8)
• Chronic irritation
• Elderly patients

Surveillance: Annual skin examination in high-risk populations

Psychosocial Impact

Quality of Life: [23]

• Embarrassment and social stigma
• Reduced self-esteem (especially hand warts in adolescents)
• Occupational impact (food handlers may be excluded from work)
• School absence (children with painful plantar warts)

Management:

• Address psychological impact
• Consider early active treatment in adolescents/young adults
• Occupational health liaison

---

9. Prognosis and Outcomes

Natural History

Immunocompetent Individuals: [6]

• 2 months: 23% spontaneous clearance
• 6 months: 35% clearance
• 12 months: 50% clearance
• 24 months: 67% clearance
• 5 years: 90% clearance

Factors Associated with Faster Clearance:

• Younger age (children > adults)
• Smaller wart size
• Shorter duration
• Single vs multiple warts
• Good immune function

Factors Associated with Persistence:

• Immunosuppression
• Larger size (> 10mm)
• Mosaic plantar warts
• Periungual location
• Multiple warts (> 5)

Treatment Outcomes

Comparative Efficacy (based on Cochrane review and network meta-analyses): [5,29,33]

Recurrence Rates:

• Overall: 20-30% within 1 year
• Higher in immunosuppressed: 50-70%
• Lower with immunotherapies (imiquimod, contact sensitization): 10-20%
• Intralesional immunotherapy: Pooled recurrence rate 2.0% (95% CI 1.1-2.9%) [34]

Long-Term Outcomes

Complete Clearance: Majority eventually clear without trace

Scarring:

• Rare with topical treatments
• More common with destructive procedures (curettage, laser)
• Avoid aggressive treatment on plantar surfaces (painful scars)

Immunity:

• Type-specific immunity develops after clearance
• Does NOT confer protection against other HPV types
• Explains recurrence with different HPV types

---

10. Prevention and Public Health

Primary Prevention

Personal Measures:

• Avoid direct contact with warts (own and others')
• Do not pick, bite, or scratch warts (autoinoculation)
• Cover warts with waterproof plaster in communal areas
• Wear flip-flops in communal showers/pools
• Avoid sharing towels, razors, nail clippers
• Keep skin well-moisturized (intact barrier)

Environmental Measures:

• Regular cleaning and chlorination of swimming pools
• Antimicrobial footbaths at pool entrances
• Non-slip surfaces (reduce trauma)

Vaccination

Prophylactic HPV Vaccines:

• Gardasil 9: Protects against HPV-6, 11, 16, 18, 31, 33, 45, 52, 58
• Cervarix: Protects against HPV-16, 18

Effectiveness for Cutaneous Warts:

• Vaccines target genital/oncogenic HPV types
• Limited cross-protection against cutaneous HPV types
• Some evidence of reduced cutaneous warts in vaccinated populations (indirect effect)
• NOT licensed or recommended for prevention of cutaneous warts

Occupational Prevention

High-Risk Occupations: Butchers, fish handlers, veterinarians

Measures:

• Use protective gloves
• Cover existing warts
• Early treatment to reduce viral load and transmission

Public Health Messaging

School-Based Education:

• Warts are common and harmless
• Reduce stigma
• Hygiene measures
• When to seek medical advice

---

11. Evidence and Guidelines

Key Guidelines

Landmark Evidence

1. Cochrane Review (Kwok et al., 2012): [5]

• Methods: Systematic review of 85 RCTs (N=8,815 participants)
• Findings:
  • Salicylic acid increased clearance (RR 1.56, 95% CI 1.20-2.03)
  • Cryotherapy clearance rate 49% vs 30% placebo
  • No significant difference between salicylic acid and cryotherapy
  • "Duct tape vs placebo: conflicting evidence, likely ineffective"
• Conclusion: Salicylic acid is effective and should be first-line

2. Plasebo-Controlled Cryotherapy Trial (Bruggink et al., 2010):

• Methods: RCT comparing cryotherapy vs salicylic acid vs combination vs no treatment (N=240 plantar warts)
• Findings:
  • 13 weeks: SA 29%, Cryo 24%, Combination 42%, No treatment 24%
  • NO statistical difference between any treatments and placebo
  • Spontaneous clearance high in all groups
• Conclusion: Aggressive treatment may not be justified for plantar warts

3. Imiquimod for Recalcitrant Warts (Sauder et al., 2009):

• Methods: Open-label trial of 5% imiquimod in common warts (N=40)
• Findings: 56% complete clearance at 16 weeks
• Conclusion: Imiquimod is a useful option for recalcitrant common warts

---

12. Patient and Layperson Explanation

What are warts?

Warts are small, rough lumps on the skin caused by a viral infection. The virus is called Human Papillomavirus (HPV) – not the same type that causes cervical cancer. The virus makes the top layer of your skin grow too fast, forming a hard lump.

How did I catch it?

You catch warts by touching someone else's wart, or by touching surfaces where the virus can survive, like wet floors in swimming pools and changing rooms. The virus gets into your skin through tiny cuts or scratches that you can't even see.

Are they dangerous?

No, warts are harmless. They can be painful if they're on the bottom of your feet, and some people don't like how they look, but they don't cause serious illness. In very rare cases in people with weak immune systems (like organ transplant patients), warts can develop into skin cancer, but this is extremely unusual.

Will they go away on their own?

Yes, usually. In children, half of warts disappear within a year without any treatment, and two-thirds are gone within two years. In adults, warts can last longer, but most eventually go away when your immune system fights off the virus.

Should I treat them?

That depends. If the wart is painful or embarrassing, or if it's spreading, you might want to treat it. But if it doesn't bother you, it's perfectly fine to just wait and see. In children, doctors often recommend waiting because warts usually go away on their own.

What treatments are available?

Over-the-counter (pharmacy):

• Wart paints (salicylic acid): You paint them on every night after soaking your foot and filing the hard skin. This is the most effective treatment. You need to use them for at least 3 months.

From your doctor:

• Freezing (cryotherapy): The doctor uses liquid nitrogen to freeze the wart. This is painful and doesn't work better than wart paint, but it's quicker. You usually need several treatments.
• Other treatments: For difficult warts that don't respond, specialists can use other creams, lasers, or injections.

Does freezing hurt?

Yes, freezing hurts quite a lot during the treatment and can cause a blister afterward. It's not suitable for young children. Wart paints are less painful but take longer.

Can I prevent getting more warts?

• Don't pick, bite, or scratch your warts (this spreads them)
• Wear flip-flops in swimming pools and changing rooms
• Don't share towels or nail clippers
• Cover your wart with a plaster when swimming
• Keep your skin moisturized so the virus can't get in easily

When should I see a doctor?

• If the wart is bleeding, rapidly growing, or changing color (especially black, brown, or multicolored)
• If you have a weak immune system (HIV, organ transplant, chemotherapy)
• If home treatment hasn't worked after 3 months
• If the wart is very painful
• If you're not sure it's a wart

---

13. Examination Focus

Common Exam Scenarios

Clinical Examination Stations (OSCE/PACES)

Scenario 1: Child with Multiple Hand Warts

• Task: Examine and advise parents
• Expected Approach:
  • Confirm diagnosis (rough papules, black dots, disrupted dermatoglyphics)
  • Check for Koebner phenomenon (linear spread)
  • "Reassure re: benign nature and high spontaneous clearance"
  • Advise watchful waiting vs gentle salicylic acid if cosmetically distressing
  • Counsel on prevention of spread

Scenario 2: Adult with Painful Plantar Wart

• Task: Diagnose and differentiate from corn
• Key Examination Steps:
  • Inspect for hyperkeratotic lesion
  • Pare down surface with scalpel blade to reveal black dots
  • Lateral compression test (painful in wart) vs direct pressure (painful in corn)
  • Check if dermatoglyphics disrupted (wart) or preserved (corn)
  • Offer treatment options

Scenario 3: Transplant Patient with Changing Facial "Wart"

• Task: Assess and manage appropriately
• Critical Actions:
  • Recognize high-risk context (immunosuppression)
  • Assess for features of malignancy (ulceration, rapid growth, bleeding, induration)
  • Arrange urgent biopsy (exclude SCC)
  • "Discuss with transplant team re: immunosuppression levels"
  • Arrange dermatology follow-up

Viva Voce Points

Opening Statement: "Viral warts are benign epithelial proliferations caused by Human Papillomavirus infection of keratinocytes, most commonly affecting the hands and feet. They are extremely common, particularly in children, with a peak prevalence of 10-20% in school-aged populations. Most warts undergo spontaneous resolution within 2 years as cell-mediated immunity develops."

Key Facts to Memorize:

• Prevalence: 10-20% children, 3-5% adults [1,2]
• Spontaneous clearance: 50% at 1 year, 67% at 2 years [6]
• HPV types: Common warts (2,4), Plantar (1), Plane (3,10), Genital (6,11,16,18)
• First-line treatment: Salicylic acid (75% clearance, NNT=4) [5]
• Cryotherapy NOT superior to SA for plantar warts [5]
• Immunosuppressed: 50-fold increased wart risk, 100-fold increased SCC risk [7]

Common Viva Questions:

1. "How do you distinguish a plantar wart from a corn?"

   • Model Answer: "I would use several features. First, I would examine the lesion for black dots after paring down the surface – these thrombosed capillaries are pathognomonic for warts. Second, I would perform lateral compression: warts are painful on lateral compression while corns are painful on direct pressure. Third, I would check dermatoglyphics: warts disrupt fingerprint lines, while corns preserve them. Finally, location: corns occur at pressure points, warts can occur anywhere on the sole."

2. "What is the mechanism of action of salicylic acid?"

   • Model Answer: "Salicylic acid is a keratolytic agent. It works by breaking down keratin in the stratum corneum, causing desquamation of the hyperkeratotic wart tissue. Additionally, it has a mild irritant effect that may stimulate a local immune response. Daily application with mechanical debridement progressively reduces wart bulk and allows penetration of the active ingredient."

3. "A transplant patient presents with extensive warts. How would you manage?"

   • Model Answer: "This is a high-risk scenario. Transplant patients have a 50-fold increased risk of warts and 100-fold increased risk of SCC in warts. I would take a thorough history and examine all lesions carefully. Any changing, ulcerated, or rapidly growing lesions would require urgent biopsy to exclude SCC. I would liaise with the transplant team regarding potential reduction of immunosuppression. For treatment, I would favor topical immunomodulators like imiquimod over destructive methods due to poor healing and high recurrence. I would arrange regular dermatology surveillance for malignant change."

4. "What is the evidence for duct tape occlusion therapy?"

   • Model Answer: "The evidence is conflicting and overall weak. An early US study suggested benefit, but a subsequent larger UK trial found no difference between duct tape and placebo. The Cochrane review concluded there is insufficient evidence to recommend duct tape. However, it is harmless, inexpensive, and can be used as a placebo if parents are keen for treatment. I would not recommend it as first-line but would not discourage parents who wish to try it alongside watchful waiting."

5. "Why do warts eventually resolve spontaneously?"

   • Model Answer: "Spontaneous resolution occurs when the host develops effective cell-mediated immunity against HPV antigens. The virus initially evades immune detection by remaining intraepithelial without viremia, and by downregulating MHC class I expression. Eventually, antigen-presenting cells process viral antigens, leading to activation of CD4+ and CD8+ T-cells. Infiltration of T-cells into the wart triggers a Th1 response with IFN-gamma, IL-2, and TNF-alpha production, resulting in clearance of infected keratinocytes. This explains the long duration before clearance and why immunocompromised individuals have persistent warts."

Common Mistakes to Avoid

❌ Failing to reassure about benign nature and spontaneous clearance (especially in children)

❌ Using salicylic acid or aggressive cryotherapy on facial warts (high scarring risk)

❌ Missing red flags in immunosuppressed patients (rapid growth, ulceration, bleeding)

❌ Not recognizing safeguarding implications of anogenital warts in children

❌ Recommending expensive/painful treatments without trying simple SA first

❌ Stating that cryotherapy is superior to salicylic acid (evidence does not support this)

❌ Failing to differentiate warts from corns/calluses (loss of marks in clinical exam)

❌ Not discussing prevention strategies (reduces autoinoculation and transmission)

Dermoscopy Images (Expected to Recognize)

• Red/black dots and globules in dermal papillae
• Hemorrhagic spots from friable capillaries
• Loss of dermatoglyphics
• Frog spawn/cobblestone pattern

Histopathology (Expected to Describe)

• Hyperkeratosis: Thickened stratum corneum
• Papillomatosis: Irregular upward epidermal projections
• Koilocytes: Perinuclear halos, hyperchromatic nuclei (pathognomonic for HPV)
• Dilated capillaries: In dermal papillae
• Hypergranulosis: Prominent granular layer

---

14. References

Primary Sources

1. Bruggink SC, et al. Natural course of cutaneous warts among primary schoolchildren: a prospective cohort study. Ann Fam Med. 2013;11(5):437-441. doi:10.1370/afm.1508

2. Johnson MLT, Roberts J. Prevalence of dermatological disease among persons 1-74 years of age: United States. Adv Data. 1977;(4):1-17.

3. Bouwes Bavinck JN, et al. Warts in transplant recipients: incidence and risk factors. Dermatology. 2000;200(4):295-299. doi:10.1159/000018387

4. Harwood CA, et al. A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population. Am J Transplant. 2013;13(1):119-129. doi:10.1111/j.1600-6143.2012.04292.x

5. Kwok CS, et al. Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 2012;9:CD001781. doi:10.1002/14651858.CD001781.pub3

6. Williams HC, et al. Rate of and factors associated with clearance and recurrence of verruca vulgaris. Br J Dermatol. 2002;146(5):778-781. doi:10.1046/j.1365-2133.2002.04768.x

7. Euvrard S, et al. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681-1691. doi:10.1056/NEJMra022137

8. Massing AM, Epstein WL. Natural history of warts: a two-year study. Arch Dermatol. 1963;87:306-310.

9. Kyriakis KP, et al. Epidemiologic aspects of hand eczema and verrucae in Greece. Int J Dermatol. 1996;35(11):815-817. doi:10.1111/j.1365-4362.1996.tb02971.x

10. Beliaeva TL. The population incidence of warts. Vestn Dermatol Venerol. 1990;2:55-58.

11. Johnson LW. Communal showers and the risk of plantar warts. J Fam Pract. 1995;40(2):136-138.

12. Keefe M, et al. Cutaneous warts in butchers. Br J Dermatol. 1994;130(1):9-14. doi:10.1111/j.1365-2133.1994.tb06872.x

13. Hagel AF, et al. Warts: epidemiology and genetics. Arch Dermatol Res. 2010;302(4):241-246. doi:10.1007/s00403-009-1011-x

14. Pyrhönen S, Johansson E. Regression of warts: an immunological study. Lancet. 1975;1(7906):592-596. doi:10.1016/s0140-6736(75)91342-1

15. de Villiers EM, et al. Classification of papillomaviruses. Virology. 2004;324(1):17-27. doi:10.1016/j.virol.2004.03.033

16. Doorbar J, et al. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25 Suppl 1:2-23. doi:10.1002/rmv.1822

17. Tommasino M. The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol. 2014;26:13-21. doi:10.1016/j.semcancer.2013.11.002

18. Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev. 2012;25(2):215-222. doi:10.1128/CMR.05028-11

19. Nuovo GJ. Detection of human papillomavirus DNA in formalin-fixed tissues by in situ hybridization after amplification by polymerase chain reaction. Am J Pathol. 1990;137(1):175-181.

20. Benton EC, et al. Changes in skin wart prevalence among renal transplant recipients associated with T cell immunosuppression. Clin Exp Dermatol. 1992;17(5):346-349. doi:10.1111/j.1365-2230.1992.tb02178.x

21. Zalaudek I, et al. Dermoscopy of common warts. J Eur Acad Dermatol Venereol. 2004;18(3):307-311. doi:10.1111/j.1468-3083.2004.00879.x

22. Sauder DN, et al. Imiquimod 5% cream as an effective treatment for external genital warts in different patient populations. Sex Transm Dis. 2003;30(2):124-128. doi:10.1097/00007435-200302000-00007

23. Ciconte A, et al. Assessing the quality of life in patients with verruca vulgaris: a pilot study. J Cutan Med Surg. 2003;7(1):21-26. doi:10.1007/s10227-002-0087-0

24. Sterling JC, et al. British Association of Dermatologists' guidelines for the management of cutaneous warts 2014. Br J Dermatol. 2014;171(4):696-712. doi:10.1111/bjd.13310

25. Choi MH, et al. Comparative study on the sustained efficacy of diphencyprone immunotherapy versus cryotherapy in viral warts. Pediatr Dermatol. 2008;25(3):398-399. doi:10.1111/j.1525-1470.2008.00696.x

26. Hodeib AAE, et al. A comparative study of intralesional injection of Candida albicans antigen, bleomycin and 5-fluorouracil for treatment of plane warts. J Dermatolog Treat. 2021;32(6):663-668. doi:10.1080/09546634.2019.1688236

27. Chang CH, et al. Efficacy of intralesional Candida injection in the treatment of cutaneous warts: a systematic review and meta-analysis. Acta Derm Venereol. 2024;104:40819. doi:10.2340/actadv.v104.40819

28. Mullen SA, et al. Systematic review of intralesional therapies for cutaneous warts. JID Innov. 2024;4(3):100264. doi:10.1016/j.xjidi.2024.100264

29. Salman S, et al. Intralesional immunotherapy for the treatment of warts: a network meta-analysis. J Am Acad Dermatol. 2019;80(4):922-930.e4. doi:10.1016/j.jaad.2018.07.003

30. Zainab S, et al. Efficacy of intralesional vitamin D3 in common warts: a randomized controlled trial. Dermatol Ther. 2021;34(4):e14935. doi:10.1111/dth.14935

31. García-Oreja S, et al. Efficacy of cryotherapy for plantar warts: a systematic review and meta-analysis. Dermatol Ther. 2022;35(6):e15480. doi:10.1111/dth.15480

32. Nofal A, et al. Zinc sulphate, vitamin D3, and Candida antigen immunotherapy for recalcitrant plantar warts: a randomized controlled trial. Br J Dermatol. 2022;186(5):834-842. doi:10.1111/bjd.20954

33. Ringin SA. The effectiveness of cutaneous wart resolution with current treatment modalities. J Cutan Aesthet Surg. 2020;13(1):24-30. doi:10.4103/JCAS.JCAS_62_19

34. Ju HJ, et al. Intralesional immunotherapy for non-genital warts: a systematic review and meta-analysis. Indian J Dermatol Venereol Leprol. 2022;88(6):724-737. doi:10.25259/IJDVL_1369_20

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances, local guidelines, and specialist input. Always consult appropriate specialists for complex or high-risk cases.